Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 8/20 | 1.00 |
| ▸ | NOS3 | P29474 | 7/20 | 1.00 |
| ▸ | NOS1 | P29475 | 4/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | BAD | Q92934 | 1/20 | 0.38 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | F12 | P00748 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16658453 | 0.96 | NOS2 (0.92) | NOS2NOS3NOS1SIGMAR1BCL2L1 | |
| Hydrochloric Acid SCHEMBL16650985 | 0.94 | NOS2 (0.88) | NOS2NOS3NOS1SIGMAR1BCL2L1 | |
| SCHEMBL19122728 | 0.77 | — | — | |
| SCHEMBL18774071 | 0.75 | NOS3 (0.59) | NOS2NOS3NOS1LIMK1 | |
| SCHEMBL8533330 | 0.74 | NOS3 (0.59) | NOS2NOS3NOS1SIGMAR1BCL2L1 | |
| SCHEMBL29386819 | 0.74 | NOS3 (0.59) | NOS2NOS3NOS1SIGMAR1BCL2L1 | |
| SCHEMBL8301451 | 0.74 | NOS3 (0.59) | NOS2NOS3NOS1SIGMAR1BCL2L1 | |
| SCHEMBL2624105 | 0.74 | NOS3 (0.59) | NOS2NOS3NOS1SIGMAR1BCL2L1 | |
| SCHEMBL2624104 | 0.74 | NOS3 (0.59) | NOS2NOS3NOS1SIGMAR1BCL2L1 | |
| SCHEMBL27357146 | 0.74 | NOS3 (0.59) | NOS2NOS3NOS1SIGMAR1BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387571-A1 | OXADIAZOLE DERIVATIVES AS SLPL RECEPTOR AGONISTS | Almirall S.A. (ES) | 2011-11-23 | — | — | EP | claimed |
| US-8041930-B2 | Data processing apparatus and method for controlling thread access of register sets when selectively operating in secure and non-secure domains | ARM LIMITED (GB) | 2011-10-18 | — | — | US | claimed |
| WO-2010081692-A1 | OXADIAZOLE DERIVATIVES AS SLPL RECEPTOR AGONISTS | ALMIRALL, S.A. (ES) | 2010-07-22 | — | — | WO | claimed |
| US-12570671-B2 | Substituted oxoisoindoline compounds for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4126843-B1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| CN-115605466-B | Substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| EP-4320132-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-5972975-A | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase | MERCK & CO., INC. (US) | 1999-10-26 | — | — | US | disclosed |
| EP-0649425-B1 | PYRIDINO-, PYRROLIDINO- AND AZEPINO-SUBSTITUTED OXIMES USEFUL AS ANTI-ATHEROSCLEROSIS AND ANTI-HYPERCHOLESTEROLEMIC AGENTS | UPJOHN CO (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5597816-A | Pyrazoloazepino substituted oximes useful as anti-atherosclerosis and anti-hypercholesterolemic agents | THE UPJOHN COMPANY (US) | 1997-01-28 | — | — | US | disclosed |
| US-5565468-A | 4,5,6,7-TETRAHYDROPYRAZOLO(1,5-A)PYRID-3-YL, PYRAZOLO(1,5-A)PYRID-3-YL, IMIDAZO(1,5-A)PYRIDIN-1-YL OR IMIDAZO(1,2-A)-PYRID-3-YL OXIME DERIVATIVES | THE UPJOHN COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1996018616-A1 | SUBSTITUTED 2-AMINOPYRIDINES AS INHIBITORS OF NITRIC OXIDE SYNTHASE | MERCK & CO., INC. (US) | 1996-06-20 | — | — | WO | disclosed |
| US-5523318-A | Pyrrolidino-substituted oximes useful as anti-atherosclerosis and anti-hypercholesterolemic agents | THE UPJOHN COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0649425-A1 | PYRIDINO-, PYRROLIDINO- AND AZEPINO-SUBSTITUTED OXIMES USEFUL AS ANTI-ATHEROSCLEROSIS AND ANTI-HYPERCHOLESTEROLEMIC AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1995-04-26 | — | — | EP | disclosed |
| WO-1993025553-A1 | PYRIDINO-, PYRROLIDINO- AND AZEPINO-SUBSTITUTED OXIMES USEFUL AS ANTI-ATHEROSCLEROSIS AND ANTI-HYPERCHOLESTEROLEMIC AGENTS | THE UPJOHN COMPANY (US) | 1993-12-23 | — | — | WO | disclosed |
| US-4209620-A | ASTHMA AND RHINITIS | BRISTOL-MYERS COMPANY (US) | 1980-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | DDX21, HRAS, RPL17 | NOS2 3409/4885NOS3 3704/4885NOS1 3751/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | NOS2 4845/4885NOS3 4868/4885NOS1 4754/4885 |
| US-12570671-B2 | Substituted oxoisoindoline compounds for the treatment of cancer | NR3C1, NR2C2, RIOX2 | NOS2 4057/4885NOS3 3163/4885NOS1 3473/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | NOS2 4845/4885NOS3 4868/4885NOS1 4754/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | NOS2 4845/4885NOS3 4868/4885NOS1 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.